Reactie op de consultatie van de Europese Commissie over het vergoedingensysteem van het Europees Geneesmiddelenagentschap (EMA).
Dit document is in het Engels.
Ook interessant voor je
Rare cancer drug for young patients approved
A new treatment option for adult and paediatric patients with a rare soft tissue cancer has been approved. The FDA has approved new immunotherapy drug atezolizumab (Tecentriq) for patients with advanced alveolar soft...
6 x gelezen
FDA panel calls for improved pulse oximeters, highlighting racial disparity
Experts say pulse oximeters are less accurate when used on darker skin, prompting calls for improvements in the devices. Throughout the COVID-19 pandemic, pulse oximeters have been a common tool to measure blood oxygen...
25 x gelezen
European Commission approves potential new treatment for Pompe disease
The European Commission (EC) has issued a marketing authorisation for Sanofi Genzyme’s therapy Nexviadyme (avalglucosidase alfa) for the long-term treatment of both late-onset and infantile-onset Pompe disease. Pompe...
4 x gelezen
Recente artikelen
De 3 belangrijkste trends voor LinkedIn in 2023
2 maanden geleden
Rare cancer drug for young patients approved
2 maanden geleden